BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) has been given a consensus recommendation of “Buy” by the eighteen brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, sixteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $441.64.
A number of equities research analysts have issued reports on the company. JPMorgan Chase & Co. increased their price target on BeOne Medicines from $445.00 to $460.00 and gave the stock an “overweight” rating in a research note on Thursday. Jefferies Financial Group reissued a “buy” rating and set a $470.00 target price on shares of BeOne Medicines in a research note on Thursday, November 5th. Guggenheim increased their price objective on shares of BeOne Medicines from $420.00 to $430.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Barclays raised their price objective on shares of BeOne Medicines from $415.00 to $446.00 and gave the stock an “overweight” rating in a report on Friday, November 6th. Finally, Wells Fargo & Company raised their target price on BeOne Medicines from $400.00 to $435.00 and gave the company an “overweight” rating in a report on Friday, November 6th.
View Our Latest Research Report on ONC
Insider Activity
In related news, insider Xiaodong Wang sold 31,028 shares of the firm’s stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $362.97, for a total transaction of $11,262,233.16. Following the transaction, the insider directly owned 31,028 shares in the company, valued at $11,262,233.16. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Xiaobin Wu sold 280 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $380.00, for a total value of $106,400.00. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 135,571 shares of company stock worth $48,487,792. Company insiders own 6.19% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the business. PCM Encore LLC acquired a new position in shares of BeOne Medicines during the 3rd quarter valued at $213,000. Kestra Advisory Services LLC increased its holdings in shares of BeOne Medicines by 21.2% during the 3rd quarter. Kestra Advisory Services LLC now owns 1,394 shares of the company’s stock valued at $510,000 after acquiring an additional 244 shares during the last quarter. Allworth Financial LP grew its holdings in BeOne Medicines by 101.3% during the third quarter. Allworth Financial LP now owns 153 shares of the company’s stock valued at $56,000 after purchasing an additional 77 shares during the last quarter. Baker BROS. Advisors LP boosted its holdings in BeOne Medicines by 0.3% during the third quarter. Baker BROS. Advisors LP now owns 8,832,335 shares of the company’s stock valued at $3,232,105,000 after acquiring an additional 30,768 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in BeOne Medicines by 28.0% in the 3rd quarter. Goldman Sachs Group Inc. now owns 201,873 shares of the company’s stock worth $73,873,000 after buying an additional 44,172 shares during the period. 48.55% of the stock is owned by institutional investors and hedge funds.
BeOne Medicines Stock Down 1.0%
NASDAQ:ONC opened at $399.70 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.55 and a quick ratio of 3.19. The firm’s 50-day moving average price is $373.68 and its 200-day moving average price is $329.55. BeOne Medicines has a 1-year low of $253.95 and a 1-year high of $424.73. The company has a market capitalization of $43.88 billion, a PE ratio of 50.79 and a beta of 0.63.
BeOne Medicines (NASDAQ:ONC – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $3.64 EPS for the quarter, beating analysts’ consensus estimates of $2.34 by $1.30. BeOne Medicines had a return on equity of 19.04% and a net margin of 13.86%. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.76 billion. On average, equities analysts predict that BeOne Medicines will post 9.98 EPS for the current fiscal year.
About BeOne Medicines
BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.
Featured Stories
- Five stocks we like better than BeOne Medicines
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
